KR20070033252A - 신규한 클로피도그렐 우선성 광학이성체의 이온교환수지착체와 그 제조방법 - Google Patents
신규한 클로피도그렐 우선성 광학이성체의 이온교환수지착체와 그 제조방법 Download PDFInfo
- Publication number
- KR20070033252A KR20070033252A KR1020060080339A KR20060080339A KR20070033252A KR 20070033252 A KR20070033252 A KR 20070033252A KR 1020060080339 A KR1020060080339 A KR 1020060080339A KR 20060080339 A KR20060080339 A KR 20060080339A KR 20070033252 A KR20070033252 A KR 20070033252A
- Authority
- KR
- South Korea
- Prior art keywords
- clopidogrel
- optical isomer
- resin
- exchange resin
- preferential
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F12/02—Monomers containing only one unsaturated aliphatic radical
- C08F12/04—Monomers containing only one unsaturated aliphatic radical containing one ring
- C08F12/14—Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing heteroatoms
- C08F12/30—Sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F12/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
- C08F12/34—Monomers containing two or more unsaturated aliphatic radicals
- C08F12/36—Divinylbenzene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/20—Manufacture of shaped structures of ion-exchange resins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Manufacturing & Machinery (AREA)
- Materials Engineering (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
- 클로피도그렐 우선성 광학이성체와 설폰산기를 가지는 수용성 양이온교환수지가 결합됨을 특징으로 하는 클피도그렐 우선성 광학이성체의 수지착체.
- 제 1 항에 있어서, 클로피도그렐 우선성 광학이성체와 결합되는 설폰산기를 가지는 수용성 양이온교환수지는 중량비로서 1:0.1 내지 1:10으로 결합됨을 특징으로 하는 클로피도그렐 우선성 광학이성체의 수지착체.
- 제 1 항에 있어서, 설폰산기를 가지는 수용성 양이온교환수지는 분자량 5,000 내지 1,000,000에서 선택되는 1종 이상임을 특징으로 하는 클로피도그렐 우선성 광학이성체의 수지착체.
- 제 1 항에 있어서, 설폰산기를 가지는 수용성 양이온교환수지는 스티렌 설포네이트 중합체 또는 디비닐벤젠 스티렌 설포네이트 공중합체 중에서 선택되는 1종 이상임을 특징으로 하는 클로피도그렐 우선성 광학이성체의 수지착체.
- 제 4 항에 있어서, 설폰산기를 가지는 수용성 양이온교환수지는 스티렌 설포네이트 중합체에서 선택되는 1종 이상인 중합체임을 특징으로 하는 클로피도그렐 우선성 광학이성체의 수지착체.
- 제 1 항에 있어서, 클로피도그렐 우선성 광학이성체의 수지착체 내에 남아있는 유리 설폰산기가 알카리성 물질로 차폐되어진 클로피도그렐 우선성 광학이성체의 수지착체.
- 제 6 항에 있어서, 알카리성 물질이 알카리 금속 또는 토금속, 아민류에서 선택되는 1종 이상인 클로피도그렐 우선성 광학이성체의 수지착체.
- 클로피도그렐 우선성 광학이성체와 설폰산기를 가지는 수용성 양이온교환수지가 결합된 클로피도그렐 우선성 광학이성체의 수지착체를 유효성분으로 함유하는 고형제제의 약제학적 조성물.
- 제 8 항에 있어서, 클로피도그렐 우선성 광학이성체와 결합되는 설폰산기를 가지는 수용성 양이온교환수지는 중량비로서 1:0.1 내지 1:10으로 결합된 클로피도그렐 우선성 광학이성체의 수지착체임을 특징으로 하는 고형제제의 약제학적 조성물.
- 클로피도그렐 유리염기의 우선성 광학이성체와 설폰산기를 가지는 수용성 양이온교환수지가 액체상태로 접촉되어 수득됨을 특징으로 하는 클로피도그렐 우선성 광학이성체 수지착체의 제조방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20050087628 | 2005-09-21 | ||
KR1020050087628 | 2005-09-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070033252A true KR20070033252A (ko) | 2007-03-26 |
KR100736024B1 KR100736024B1 (ko) | 2007-07-06 |
Family
ID=37889044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060080339A KR100736024B1 (ko) | 2005-09-21 | 2006-08-24 | 신규한 클로피도그렐 우선성 광학이성체의 이온교환수지착체와 그 제조방법 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20080226579A1 (ko) |
EP (1) | EP1926736A4 (ko) |
JP (1) | JP2009507014A (ko) |
KR (1) | KR100736024B1 (ko) |
CN (1) | CN101253179B (ko) |
AU (1) | AU2006292946B2 (ko) |
CA (1) | CA2618187C (ko) |
WO (1) | WO2007035028A1 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090163449A1 (en) * | 2007-12-20 | 2009-06-25 | Eastman Chemical Company | Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives |
EP2377520A1 (de) * | 2010-03-24 | 2011-10-19 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung des Prasugrels |
JPWO2015045604A1 (ja) * | 2013-09-30 | 2017-03-09 | 富士フイルム株式会社 | 口腔内崩壊錠 |
WO2018203548A1 (ja) * | 2017-05-01 | 2018-11-08 | 日産化学株式会社 | 水溶性が改善されたアニオン性高分子化合物の調製方法 |
CN111060625B (zh) * | 2019-12-31 | 2022-04-05 | 北京鑫开元医药科技有限公司 | 2-(噻吩-2-基)乙基对甲苯磺酸酯及其异构体的检测方法 |
KR20230126068A (ko) | 2022-02-22 | 2023-08-29 | 인제대학교 산학협력단 | 양이온교환수지를 사용한 약물의 방출 조절을 위한 조성물 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2990332A (en) * | 1958-04-02 | 1961-06-27 | Wallace & Tiernan Inc | Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith |
US3138525A (en) * | 1961-06-16 | 1964-06-23 | Hoffmann La Roche | Castor wax-amprotropine-resin compositions |
US3608063A (en) * | 1969-08-15 | 1971-09-21 | Gilbert S Banker | Molecular drug entrapment process and compositions |
US3901248A (en) * | 1970-07-22 | 1975-08-26 | Leo Ab | Chewable smoking substitute composition |
US3987163A (en) * | 1973-07-27 | 1976-10-19 | Burton, Parsons And Company, Inc. | Polystyrene sulfonate containing opthalmic solutions |
US4369175A (en) * | 1981-07-27 | 1983-01-18 | Ciba-Geigy Corporation | Process for the manufacture of prolonged action vincamine preparations, the vincamine preparations so obtained, and medicaments containing them |
US4459278A (en) * | 1983-03-07 | 1984-07-10 | Clear Lake Development Group | Composition and method of immobilizing emetics and method of treating human beings with emetics |
US4762709A (en) * | 1983-09-16 | 1988-08-09 | Pennwalt Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
US4788055A (en) * | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
FR2623810B2 (fr) * | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it |
US5219563A (en) * | 1988-05-11 | 1993-06-15 | Glaxo Group Limited | Drug adsorbates |
US4996047A (en) * | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
SE9103110D0 (sv) * | 1991-10-24 | 1991-10-24 | Kabi Pharmacia Ab | New drug formulation |
FR2744918B1 (fr) * | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
US5980882A (en) * | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
FR2779726B1 (fr) * | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
FR2792836B3 (fr) * | 1999-04-30 | 2001-07-27 | Sanofi Sa | Composition pharmaceutique sous forme unitaire contenant de l'aspirine et de l'hydrogenosulfate de clopidogrel |
US6514492B1 (en) * | 1999-07-14 | 2003-02-04 | Schering-Plough Veterinary Corporation | Taste masking of oral quinolone liquid preparations using ion exchange resins |
SE9904377D0 (sv) * | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
US6800668B1 (en) * | 2001-01-19 | 2004-10-05 | Intellipharmaceutics Corp. | Syntactic deformable foam compositions and methods for making |
US6767913B2 (en) * | 2001-12-18 | 2004-07-27 | Teva Pharmaceutical Industries Ltd. | Crystal forms iii, iv, v, and novel amorphous form of clopidogrel hydrogensulfate, processes for their preparation, processes for the preparation of form i, compositions containing the new forms and methods of administering the new forms |
US6800759B2 (en) * | 2002-08-02 | 2004-10-05 | Teva Pharmaceutical Industries Ltd. | Racemization and enantiomer separation of clopidogrel |
CZ297472B6 (cs) | 2002-08-27 | 2006-12-13 | Zentiva, A.S. | Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I |
ITMI20022228A1 (it) * | 2002-10-21 | 2004-04-22 | Dinamite Dipharma S P A | Sali di clopidogrel con acidi alchil-solforici. |
DE10305984A1 (de) * | 2003-02-13 | 2004-09-02 | Helm Ag | Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen |
US20050059696A1 (en) * | 2003-05-08 | 2005-03-17 | Dr. Reddy's Laboratories Limited | Process for the recovery of S -(+)-methyl- (2-chlorophenyl)- (6,7-dihydro- 4H-thieno [3,2-c] pyrid-5-yl) acetate hydrogen sulfate (clopidogrel bisulfate) from its (R) and mixture of (R) and (S)- isomers |
US8029822B2 (en) * | 2003-05-22 | 2011-10-04 | Osmotica Kereskedelmi és Seolgáltató KFT | Rupturing controlled release device having a preformed passageway |
US20050036977A1 (en) * | 2003-08-11 | 2005-02-17 | Dilip Gole | Taste-masked resinate and preparation thereof |
US20050112198A1 (en) * | 2003-10-27 | 2005-05-26 | Challapalli Prasad V. | Bupropion formulation for sustained delivery |
US20050181050A1 (en) * | 2004-01-28 | 2005-08-18 | Collegium Pharmaceutical, Inc. | Dosage forms using drug-loaded ion exchange resins |
DE102005060690B4 (de) * | 2005-12-15 | 2008-09-25 | Capsulution Nanoscience Ag | Salze von Clopidogrel mit Polyanionen und ihre Verwendung zur Herstellung pharmazeutischer Formulierungen |
-
2006
- 2006-08-24 KR KR1020060080339A patent/KR100736024B1/ko active IP Right Grant
- 2006-08-24 US US12/065,104 patent/US20080226579A1/en not_active Abandoned
- 2006-08-24 CN CN2006800320268A patent/CN101253179B/zh not_active Expired - Fee Related
- 2006-08-24 AU AU2006292946A patent/AU2006292946B2/en not_active Ceased
- 2006-08-24 EP EP06783733A patent/EP1926736A4/en not_active Withdrawn
- 2006-08-24 WO PCT/KR2006/003346 patent/WO2007035028A1/en active Application Filing
- 2006-08-24 CA CA2618187A patent/CA2618187C/en not_active Expired - Fee Related
- 2006-08-24 JP JP2008528932A patent/JP2009507014A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN101253179A (zh) | 2008-08-27 |
CN101253179B (zh) | 2010-12-29 |
US20080226579A1 (en) | 2008-09-18 |
WO2007035028A1 (en) | 2007-03-29 |
KR100736024B1 (ko) | 2007-07-06 |
CA2618187C (en) | 2011-06-21 |
AU2006292946A1 (en) | 2007-03-29 |
CA2618187A1 (en) | 2007-03-29 |
EP1926736A4 (en) | 2010-08-25 |
JP2009507014A (ja) | 2009-02-19 |
EP1926736A1 (en) | 2008-06-04 |
AU2006292946B2 (en) | 2009-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK168934B1 (da) | Lægemiddeladsorbater, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende adsorbaterne | |
KR100736024B1 (ko) | 신규한 클로피도그렐 우선성 광학이성체의 이온교환수지착체와 그 제조방법 | |
UA110945C2 (uk) | Пероральна фармацевтична композиція на основі налбуфіну (варіанти) | |
EP2732810A1 (en) | Spherical particles of clopidogrel bisulfate, pharmaceutical composition including same, and method for manufacturing same | |
ZA200509155B (en) | Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same | |
JP7403647B2 (ja) | レバムロジピンベシル酸塩水和物含有組成物及びその調製方法 | |
JP2019112424A (ja) | トホグリフロジンを含有する固形製剤及びその製造方法 | |
WO1995015155A1 (en) | Taste masked composition containing a drug/polymer complex | |
EP2563340A2 (en) | Water soluble pharmaceutical composition | |
ES2277960T3 (es) | Base libre de la amlodipina. | |
SK302003A3 (en) | Stable gabapentin having pH within a controlled range | |
KR102276281B1 (ko) | 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염 | |
JPH03120211A (ja) | 粒状カルニチン製剤 | |
EP2303233A1 (en) | Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof | |
CA2543757A1 (en) | Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or cholic acid derivatives | |
CA2865312A1 (en) | Taste masked dispersible tablets | |
WO1999041233A1 (en) | A watersoluble nimesulide adduct also for injectable use | |
CA2029667A1 (en) | Process | |
KR100700721B1 (ko) | 안정성 및 용출율이 향상된 s(+)-이부프로펜의 정제 | |
KR100837843B1 (ko) | 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물 | |
JP2023183350A (ja) | ラコサミド固形製剤 | |
KR20110056480A (ko) | 결정형 에스조피클론, 이의 조성물, 이의 제조방법 및 이의 용도 | |
JPH023609A (ja) | 塩酸ニカルジピンを活性成分とする持効性製剤 | |
JP2008105969A (ja) | 酒石酸ゾルピデム組成物 | |
KR20130037802A (ko) | 프라미펙솔을 포함하는 서방성 미립자 및 이를 포함하는 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130409 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140515 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150423 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160530 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170512 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190325 Year of fee payment: 13 |